Synthesis runs a world-class retreat center in Amsterdam that provides medically supervised, multi-day group psychedelic experiences using legally available psilocybin-containing truffles. The company emphasizes comprehensive medical screenings, one-to-one preparation and post-experience integration, and a communal model intended to maximize safety and transformational outcomes. Approximately 1,000 people have booked retreats with Synthesis over the prior two years, and the company reports trial results with Imperial College London showing a 10% increase in well-being, a 42% decrease in depressive symptoms, a 14% decrease in anxiety, and a roughly 120% increase in connectedness at four weeks. Until now Synthesis has excluded people diagnosed with depression or PTSD from its primary retreats but is developing clinical protocols and additional supports to treat people with depression and those on antidepressants. The company plans to turn learnings into tools and services for the broader psychedelic ecosystem, including a consumer education product and a 12-month practitioner training program that includes supervised experiential components. Financially, Synthesis announced its first institutional funding round of $2.75 million led by Novamind Ventures to support capacity building and product development.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2020